72.11.Z - Research and experimental development on biotechnology
21.20.Z - Manufacture of medicines and other pharmaceutical products
46.46.Z - Wholesale of pharmaceutical goods
72.19.Z - Other research and experimental development on natural sciences and engineering
74.90.Z - Other professional, scientific and technical activities not elsewhere classified
85.59.B - Other out-of-school forms of education, not elsewhere classified
86.10.Z - Hospital activities
86.21.Z - General medical practice activities
86.22.Z - Specialist medical practice activities
86.90.E - Other human health activities notelsewhere classified
2022 | 2023 | ||
---|---|---|---|
K PLN | K PLN | % | |
Profit (loss) on sale | -2,8 | -3,8 | -34,5 |
Gross profit (loss) | -2,8 | -3,8 | -34,5 |
EBITDA | -2,8 | -3,8 | -34,5 |
Short time liabilities | 0 | 0 | 0 |
Other operating costs | 0 | 0 | 0 |
Equity capital | 3,2 | -0,6 | -118,8 |
Operating profit (EBIT) | -2,8 | -3,8 | -34,5 |
Assets | 3,2 | 0,8 | -75,8 |
Net profit (loss) | -2,8 | -3,8 | -34,5 |
Cash | 1,6 | 0,4 | -74,2 |
Net income from sale | 0 | 0 | 0 |
Liabilities and provisions for liabilities | 0 | 1,4 | -∞ |
Working assets | 1,6 | 0,7 | -60,2 |
Other income costs | 0 | 0 | 0 |
Depreciation | 0 | 0 | 0 |
% | % | p.p. | |
Profitability of capital | -88,3 | 632,2 | 720,5 |
Equity capital to total assets | 100 | -77,6 | -177,6 |
Days | Days | Days | |
Short term commitment turnover cycle | 0 | 0 | 0 |
Net dept to EBITDA | 0.5809274911880493 | -0.25076162815093994 | -0,9 |
Opinie dotyczące usług, produktów oraz działalności firmy nie są weryfikowane